Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Good financial results growth rate 17.6% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (6.2%)
  • Dividend yield for the last twelve months 2.9%
  • Free cash flow yield 0.0% (LTM)
  • Share price is 15.1% higher than minimum and 10.6% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (14.2x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (+0.4%)166.25
year average price 155.04  


year start price 162.47 2023-09-18

min close price 144.38 2024-05-28

max close price 167.38 2024-09-10

current price 165.52 2024-09-16
Common stocks: 2 631 399 832

Dividend Yield:  2.9%
EV / LTM EBITDA: 14.2x
EV / EBITDA annualized: 8.5x
Last revenue growth (y/y):  -12.1%
Last growth of EBITDA (y/y):  +47.4%
Historical revenue growth:  -0.4%
Historical growth of EBITDA:  +12.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 437 470
Net Debt ($m): 32 590
EV (Enterprise Value): 470 060
EBITDA LTM ($m): 33 156
EV / LTM EBITDA: 14.2x
Price to Book: 6.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-09-16zacks.com

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

2024-09-16prnewswire.com

Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer

2024-09-15prnewswire.com

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

2024-09-14prnewswire.com

RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer

2024-09-14prnewswire.com

RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

2024-09-12zacks.com

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

2024-09-12globenewswire.com

Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis

2024-09-11youtube.com

Chief Future Officer: Joseph Wolk, Johnson & Johnson Executive VP & CFO

2024-09-11youtube.com

J&J CFO Sees Value in Tech Partnerships

2024-09-11youtube.com

How J&J's CFO Keeps His Footing on the 'Patent Cliff'
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data